Votrient (pazopanib) — United Healthcare

Initial criteria

• Diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer AND (disease is persistent OR recurrent)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Votrient therapy

Approval duration

12 months